ABX-002 Bioequivalence and Effect of Food Study in Healthy Adult Participants

The goal of this study is to assess the bioequivalence (BE) between the liquid formulation and the new solid formulation of ABX-002 under fasting conditions and to evaluate the effect of food on the pharmacokinetics (PK) of the new solid formulation of ABX-002.This study design is consistent with FDA guidelines for the assessment of BE. This was an open label, randomized, single dose, three-way crossover BE and food-effect study. Therefore, the total number of participants in this study was 18.

NCT Number	NCT07652697
Lead Sponsor	Autobahn Therapeutics, Inc.
Conditions	Healthy
Enrollment	18 participants
Start Date	2025-01-02
Primary Completion	2025-02-17 (estimated)
Study Completion	2025-02-17 (estimated)
Updated on ClinicalTrials.gov	2026-06-17